Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping (Q51499722)

6 April 2018

title

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping (English)

1 reference

6 April 2018

1 reference

Kearns GL

1 reference

6 April 2018

author name string

Kashuba AD

1 reference

6 April 2018

Nafziger AN

1 reference

6 April 2018

Leeder JS

1 reference

6 April 2018

Gotschall R

1 reference

6 April 2018

Rocci ML Jr

1 reference

6 April 2018

Kulawy RW

1 reference

6 April 2018

Beck DJ

1 reference

6 April 2018

Bertino JS Jr

1 reference

6 April 2018

language of work or name

English

0 references

publication date

1 September 1998

1 reference

6 April 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

6 April 2018

volume

1 reference

6 April 2018

issue

1 reference

6 April 2018

page(s)

257-268

1 reference

6 April 2018

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Effect of allopurinol on caffeine disposition in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Clinical pharmacokinetics of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Clinical pharmacokinetics of fluvoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

A fluvoxamine-caffeine interaction study

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Development of a questionnaire for detecting potential adverse drug reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Nomenclature for human CYP2D6 alleles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Variability in caffeine metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

A urinary metabolite ratio that reflects systemic caffeine clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Caffeine as a metabolic probe: validation of its use for acetylator phenotyping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Clinical Pharmacy: Case Studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

Prediction of creatinine clearance from serum creatinine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990174-6

10.1016/S0009-9236(98)90174-6

7 January 2021

Identifiers

DOI

1 reference

6 April 2018

1 reference

6 April 2018